Kyle Lumsden, APRN
Family · Honolulu, HINPI 1487326963
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 42.8% of the total.
Across 123 payments — averaging $24.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Pfizer$390
- Boston Scientific$212
- Teva Pharmaceuticals USA, Inc.$154
- Genentech USA, Inc.$141
- Medtronic$130
- plus $717 from 15 others
What the payments were for
- Food & beverage$3,049100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 54 | $1,305 |
| Pfizer | 23 | $390 |
| Boston Scientific | 4 | $212 |
| Teva Pharmaceuticals USA, Inc. | 8 | $154 |
| Genentech USA, Inc. | 6 | $141 |
| Medtronic | 1 | $130 |
| Vanda Pharmaceuticals Inc. | 1 | $125 |
| Lundbeck LLC | 5 | $115 |
| Banner Life Sciences, LLC | 4 | $90 |
| Eisai Inc. | 3 | $70 |
| Cycle Pharmaceuticals Inc | 2 | $52 |
| Amneal Pharmaceuticals LLC | 2 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Jazz Pharmaceuticals Inc. | 1 | $31 |
| Acadia Pharmaceuticals Inc | 1 | $27 |
| Novartis | 1 | $26 |
| Neurelis, Inc. | 1 | $25 |
| Upsher-smith Laboratories LLC | 1 | $22 |
| UCB, Inc. | 1 | $21 |
| EMD Serono, Inc. | 1 | $16 |
| SK Life Science, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LINQ II$130
- Fanapt$125
- UBRELVY$125
- NURTEC ODT$121
- WATCHMAN FLX$112
How this compares
$3,049 in reported general payments places this provider in the 85th percentile of 466 family providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 28 | $152,747 |
| Nurtec OdtRimegepant Sulfate | 61 | $91,651 |
| QuliptaAtogepant | 36 | $48,942 |
| RytaryCarbidopa/Levodopa | 36 | $47,189 |
| NeuproRotigotine | 22 | $25,188 |
| UbrelvyUbrogepant | 15 | $21,026 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 24 | $16,724 |
| Memantine Hcl | 61 | $3,696 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 84 | $3,325 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 40 | $2,699 |
| AmantadineAmantadine Hcl | 37 | $2,507 |
| Zolmitriptan OdtZolmitriptan | 16 | $1,842 |
| Naratriptan Hcl | 30 | $1,247 |
| Sumatriptan Succinate | 22 | $649 |
| Gabapentin | 27 | $428 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $27 | $152,74728 claims |
| PfizerNurtec Odt | $390 | $91,65161 claims |
| AbbVieQulipta, Ubrelvy | $1,305 | $69,96851 claims |
| Amneal Pharmaceuticals LLCRytary | $44 | $47,18936 claims |
| UCB, Inc.Neupro | $21 | $25,18822 claims |
| Upsher-smith Laboratories LLCTopiramate | $22 | $34518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 466 family providers in Hawaii.
Other family in Honolulu
- Joey SesonHonolulu$48K
- Kanna DokgoHonolulu$26K
- John MosesHonolulu$24K
- Leif MarzHonolulu$11K
- Ia Lynne AranaHonolulu$9K
- Josette DudoitHonolulu$8K
- Kailie WongHonolulu$6K
- Jane StinsonHonolulu$6K
- Melissa leHonolulu$6K
- Karen RowanHonolulu$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.